Amgen

Amgen’s Experimental New Type of Cholesterol-Fighting Drug Meets Primary Goal

Amgen Inc announced their experimental new type of cholesterol-fighting injectable drug evolocumab has been able to meet its primary goal. It registered success by reducing 'bad' LDL cholesterol in patients having a genetic tendency of having high levels of the artery-clogging fat.

AustrianTribune Specials

Yet again, NASA has postponed the launch of rocket from the Eastern Shore of Virginia. NASA said due to poor scientific conditions, boats wandered into the hazard zone during launch preparations, which led it to postpone the launch of SubTec-6....

Most Popular

Pablo Escobar, the drug lord of Colombia, may have died...

The Farmington Daily Times has revealed in a recent...

Gov. Jerry Brown scrapped a law that was passed last...

Automotive News

  • Takata could face $500-million US charge and 2014 net loss due to massive airbag recall
  • Government says there is no need to park GM cars affected by ignition-switch recall
  • Mark Fields to replace Ford CEO Alan Mulally with effect from July 1
  • Nearly nine hundred thousand Honda Odyssey minivans recalled

UK News

  • BT Apologizes to Customers for Internet Connection Problems
  • New Hampshire Foresters on Lookout for Miniscule Menace Infesting and Killing Ash Trees
  • Harlequin Ladybirds Feed on their British Cousins
  • Bristol researchers find 4,500-year-old food items in cupboard
  • UK Building Strategies for Robotic Future